Friday, November 22, 2013

International Stem Cell Corp. (ISCO) Receives Favorable Review in Seeking Alpha Article

International Stem Cell was recently the topic of a Seeking Alpha article by contributing writer Kingmaker, who outlines the company’s stem cell technology, third-quarter financial results, its upcoming investigational new drug (IND) filing, and its subsequent market potential.

To read the full article visit: http://seekingalpha.com/article/1857401

International Stem Cell is a biotech company developing new stem cell technology based on a natural process called parthenogenesis, in which stem cells are derived from unfertilized human eggs.

As the author notes, International Stem Cell’s parthenogenesis stem cells “demonstrate superiority” in meeting key criteria in order to be effectual in therapeutic application. With its scientific developments firmly in place, the company is also working to strengthen its financial position.

“Given that the company appears to be on track with its science, investors are likely wondering if they should invest now. I believe the answer is a resounding yes,” the author says.

International Stem Cell reported record third-quarter revenues of $1.67 million, a year-over-year increase of 41 percent, while cutting general and administrative expenses by approximately 13 percent and ending the quarter with roughly $1.8 million in available cash.

The article also briefly discusses the company’s Parkinson’s disease program and its anticipated IND filing with the FDA through a partnership with Duke University. International Stem Cell’s aims to develop a product to eliminate Parkinson’s disease, which is the second most common neurodegenerative disease affecting 7-10 million people worldwide.

“As the biotechnology bull market rages on, investors are likely looking for the next niche that can take off. Despite a lot of controversy, I believe that stem cells are that next area to advance medicine to heights never thought possible. International Stem Cell Corporation is quickly gaining recognition with both the medical and investing communities. With several catalysts occurring over the next 12-18 months, investors should get in early before it’s too late,” Kingmaker states in his conclusion.

For more information, visit www.internationalstemcell.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.

Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net

No comments: